Genitourinary Drugs Market Size, Industry Analysis Report, Regional Outlook (U.S., Germany, UK, Italy, Russia, China, India, Japan, South Korea, Brazil, Mexico, Saudi Arabia, UAE, South Africa), Application Growth Potential, Competitive Market Growth & Forecast, 2016 – 2024
Report ID: GMI1382
Genitourinary Drugs Market size will witness a considerable growth over the forecast period.
Increasing prevalence of genitourinary disorders, rising disposable incomes, and constant improvements in healthcare infrastructure will drive genitourinary drugs market over the forecast timeframe.
Patients with diabetes are highly susceptible to suffer from urinary tract infections. Women are more disposed to this problem due to the short length of urethra that facilitates easier entry of microorganisms. Global prevalence of diabetes is projected to reach up to 552 million by 2030 from 366 million in 2011, as per the statistics by International Diabetes Federation. Tremendous growth in diabetes prevalence should also boost the demand for genitourinary drugs over the coming years.
Lack of therapy compliance and continual patent expirations may hamper the overall genitourinary drugs market growth. Invasion of a wide range of generics by major- and medium-sized pharmaceutical companies is likely to constrain the industry growth.
Prostate cancer contributed to over 25% revenue share in 2015. A wide range of therapeutics, such as radiopharmaceuticals, immunotherapy medication, and anti-neoplastic agents, available to treat prostate cancer will drive this segment’s growth. According to National Cancer Institute (NCI), the total number of new prostate cancer cases between 2009 to 2013 were 129.4 per 100,000 men every year.
Urinary Tract Infections (UTIs) affect more than 150 million people every year worldwide, resulting in direct healthcare expenses of over USD 6 billion. Around 2.4 percent of women and men will be detected with bladder cancer at some point during their lifetime.
Hormonal therapy dominated the segment in 2015 due to increasing usage of medicines; however, anti-infective drugs should witness a healthy growth over the forecast period with increasing rate of urinary tract infections. The presence of an extensive drug pipeline for reproductive disorders in women may boost sales of the gynecological products over the coming years.
U.S. genitourinary drugs market size held a large share of the global genitourinary drugs in 2015 due to robust healthcare infrastructure, growing awareness, and technological advancements in the development of genitourinary drugs.
Canada genitourinary drugs market share is driving due to the burden of cancer disease in the country. As per the Canadian Cancer Statistics in 2015, about 196,900 people diagnosed with cancer.The data is important to focus on prevention efforts, in both primary prevention and secondary prevention of cancer, and allow more effective treatment of certain cancer through earlier detection.
Europe genitourinary drugs market will witness a significant growth over the forecast timeframe. It was estimated that over 78% of the new cancer medicines that were introduced between 2010 and 2014 are available within the greater EU. In 2012, Germany’s GDP accounted for over USD 34,706.8 per capita, driving the industry growth.
APAC should witness a lucrative growth during the forecast period owing to the increasing R&D in China and India, high disposable income, and growing awareness in these emerging countries.
Some of the companies operating in this industry include Abbott Laboratories, Astellas, Bayer, Bristol-Myers Squibb, Eli Lilly, Pfizer, Genentech, GlaxoSmithKline, Merck, Hoffman-La Roche, Immunex, and Ionis Pharmaceuticals.
High R&D expenditure by global players will drive industry innovation. Industry participants are developing novel products to gain competitive market leverage over their peers.
Companies are focusing on the implementation of strategies including mergers & acquisitions, new product development, and regional expansion. In October 2016, the U.S. FDA approved a supplemental Biologics License Application (sBLA) of Bristol-Myers Squibb, to enlarge the practice of Opdivo (nivolumab) to treat patients suffering from an advanced form of bladder cancer. Similarly, in June 2016, the U.S. National Surgical Adjuvant Breast and Bowel Project (NSABP) and Bayer, collaborated on a new Phase III trial to study Stivarga (regorafenib) tablets as an adjuvant therapy in colon cancer. Growing geographical presence of the industry players is expected to raise the awareness levels regarding treatment options for genitourinary diseases among the patients and the doctors.
What Information does this report contain?
Request for Customization
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Why Global Market Insights?Comprehensive Research
- All-inclusive coverage
- In-depth and granular data (ex: information for 8 to 15 countries, with clients open to add to this list, in each report)
- Penetrative insights & latest trends
- Offers holistic understanding of the market
- Unique methodology
- Iterative in nature to eliminate errors
- Detailed methodology, scope, assumptions and data sources available for reference
- Committed to making a positive difference for our clients
- Given the nature of this industry, we are committed to ensure that our clients get maximum return on their investment in our services
- Every purchase comes with an option to obtain additional information:
- up to 10% of the original cost
- 45-minute analyst tele-call to obtain further clarity on the market.
- Global Market Insights, Inc. strictly adheres to PCI-DSS security norms.
- Only PCI-DSS compliant payment methods used for highest level of client data security
Connect with our sales team